skila News

Pharmaceutical companies must do more with less, and as a result are turning to Skila to find better ways to collaborate around key business processes and workflows.

Skila, the life science industry’s leading provider of knowledge agility and stakeholder collaboration management solutions, announces the extension and expansion of solution contracts with two top Pharma companies

A global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health has selected Skila’s iKOL™ Expert Database solution.

Moish Tov, Chairman and CEO of Skila, is pleased to announce the appointment of David Batten to the newly created position of President. In this role, Batten will lead the organization's strategic planning, partnership and M&A initiatives.

Two top-ten Pharma companies have extended and expanded their current agreements with Skila, the industry’s leader in knowledge agility and stakeholder collaboration management.

Skila’s Dr. Susan Dorfman and Pragmedic's Dr. Brian D. Smith have been featured at eyeforpharma’s Market Access Europe 2010 Conference in London, focusing on their editorial in the Journal of Medical Marketing’s special Market Access issue.

Skila has four of its experts featured in Volume 10.1 of the Journal of Medical Marketing. “Pricing, Market Access and the Return of Reality” is the title of the latest volume of the prominent peer-reviewed Journal of Medical Marketing.

Skila, a leading provider of knowledge agility and stakeholder collaboration management solutions, today announced a new and expanded Master Services Agreement (MSA) with Nycomed.

Skila, a leading provider of knowledge agility and stakeholder collaboration management solutions, announces that a Top-20 US pharmaceutical company has chosen Skila’s Launch Readiness™ solution for two of its upcoming product launches.

iKOL offers real-time knowledge® of more than 2.5 million leading thought leaders representing 400+ disease areas in more than 60 leading countries across thousands of hospitals and institutions.

Skila, A Sela2 Company, has recently expanded its active client base by closing nine expansions across five current clients in Q4 of its fiscal year, ending September 30, 2009.

Skila announces the launch of two new state-of-the-art solutions for facilitating launch preparation and clinical trial tracking in the life science industry.

Skila’s iAdvocate Mobile™ solution enhances the iAdvocate™ opinion leader management solution by enabling users to quickly and easily access their iAdvocate™ solution from smart phones.

Skila, A Sela2 Company, announces the addition of mobile capabilities for Skila solutions. Skila’s mobile solutions allow knowledge agility by enabling users to quickly and easily access their Skila solutions from smart phones.

Susan Dorfman, VP Global Marketing, and Sara Melo-Pereira, Director of Global Marketing, Skila have recently released an article in Pharmaceutical Executive regarding the challenges in measuring the value of KOL interactions with field medical teams.

Skila, A Sela2 Company, announces the launch of the 11.0 version of its technology platform.

Skila, a Sela2 Company, the leading provider of knowledge agility solutions, was included in the list of “Cool Vendors” in the "Cool Vendors in Life Sciences, 2009, Dale Hagermeyer, March 23, 2009" report by Gartner Inc.

Skila’s Simon Mason, COO, received the highest speaker ratings at CBI’s Premier Bio/Pharmaceutical Forum on Integrated Opinion Leader Management Systems conference, for his presentation entitled “Key Tenets of Thought Leader Management.”

Skila’s Susan Dorfman, VP Global Marketing, will Chair CBI’s Premier Bio/Pharmaceutical Forum on Integrated Opinion Leader Management Systems being held in King of Prussia, PA.

Skila's Susan Dorfman, VP of Global Marketing, is named in the 2008 PharmaVoice 100 as a “Brand Champion with the strategic know-how, market insights, and a creative flair that differentiates their products from the competition.”

Skila, the Intelligration® Company, secured a loan from MMV Financial.

On July 24, 2008, Skila’s Susan Dorfman, VP Global Marketing, will co-moderate a Wharton Club of New Jersey Panel Discussion entitled “Business Implications of Pending Pharma Sales & Marketing Regulations”.

Karen Massand, Managing Director of the Strategic Advisory Group at Skila, is sharing her experience regarding the challenges that clinical operations groups are facing in the life science industry in the June 2008 issue of PharmaVoice.

Skila has announced the release of iAdvocate 2.5, a KOL Management Solution for Medical & Marketing teams in Life Sciences. The solution has been enhanced and the 360° profile has been redesigned to deliver even more relevant and timely information.

Skila continues to build its momentum and global Life Sciences client base by adding five new named clients and six major client expansions across Europe and U.S. in the last quarter.

Susan Dorfman, Vice President of Global Marketing from Skila, conveys her opinions regarding the ramifications and implications of the Safe Rx Act in the article entitled “Licensed to Sell”, which appears in the April 2008 issue of PharmaVoice.